Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.91 -16.6%	$1.95	$1.33 ▼ $3.58	$107.88M	0.74	103,074 shs	151,120 shs
AQST Aquestive Therapeutics	$3.78 -2.1%	$3.73	$2.12 ▼ $5.80	$383.41M	1.99	969,545 shs	1.63 million shs
ARCT Arcturus Therapeutics	$14.89 +30.7%	$13.15	$8.04 ▼ $25.88	$308.90M	2.26	416,069 shs	1.81 million shs
SLDB Solid Biosciences	$6.04 -0.7%	$5.50	$2.41 ▼ $10.37	$471.29M	2.44	1.48 million shs	1.67 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+5.53%	+17.50%	+19.90%	+33.14%	+2.69%
AQST Aquestive Therapeutics	-1.03%	-3.98%	-3.74%	+68.56%	+12.54%
ARCT Arcturus Therapeutics	-4.37%	-6.64%	-17.34%	-3.96%	-37.00%
SLDB Solid Biosciences	-3.40%	-10.91%	+15.51%	+117.78%	-17.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.9829 of 5 stars	3.5	5.0	2.6	1.7	0.0
AQST Aquestive Therapeutics	1.847 of 5 stars	3.5	3.0	2.4	0.0	0.0
ARCT Arcturus Therapeutics	2.838 of 5 stars	3.5	2.0	3.0	2.5	0.6
SLDB Solid Biosciences	3.467 of 5 stars	4.6	1.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.50	292.67% Upside
AQST Aquestive Therapeutics	3.00	Buy	$10.14	168.33% Upside
ARCT Arcturus Therapeutics	3.00	Buy	$50.00	235.80% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	150.00% Upside

Current Analyst Ratings Breakdown

Latest ADAG, ARCT, AQST, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $49.00
8/12/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $42.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	899.80	N/A	N/A	$1.14 per share	1.68
AQST Aquestive Therapeutics	$57.56M	6.52	N/A	N/A	($0.66) per share	-5.73
ARCT Arcturus Therapeutics	$152.31M	2.65	N/A	N/A	$8.90 per share	1.67
SLDB Solid Biosciences	$8.09M	57.87	N/A	N/A	$3.43 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	N/A
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest ADAG, ARCT, AQST, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	-$0.34	+$0.77	-$0.34	$17.64 million	$28.30 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.30	2.30
AQST Aquestive Therapeutics	N/A	4.87	4.48
ARCT Arcturus Therapeutics	0.06	5.64	5.64
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
AQST Aquestive Therapeutics	32.45%
ARCT Arcturus Therapeutics	94.54%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
AQST Aquestive Therapeutics	7.85%
ARCT Arcturus Therapeutics	15.30%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
SLDB Solid Biosciences	100	77.51 million	66.95 million	Optionable

ADAG, ARCT, AQST, and SLDB Headlines

Recent News About These Companies

Solid Biosciences reports Q2 EPS (42c), consensus (49c)

1 hour ago | msn.com

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 12 at 4:07 PM | globenewswire.com

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside (SLDB)

...

August 12 at 3:33 PM | marketbeat.com

Knott David M Jr Invests $488,000 in Solid Biosciences Inc. (NASDAQ:SLDB)

August 12 at 8:17 AM | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from Analysts

August 11 at 2:15 AM | marketbeat.com

Solid Biosciences (SLDB) to Release Earnings on Tuesday

August 10 at 3:15 AM | americanbankingnews.com

Solid Biosciences (SLDB) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.4% - What's Next?

August 5, 2025 | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Solid Bio Green on Fast Track Nod

July 23, 2025 | baystreet.ca

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 23, 2025 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Trading 13.3% Higher - Should You Buy?

July 19, 2025 | marketbeat.com

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?

July 16, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

July 16, 2025 | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15, 2025 | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10, 2025 | investing.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10, 2025 | seekingalpha.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10, 2025 | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, ARCT, AQST, and SLDB Company Descriptions

Adagene NASDAQ:ADAG

$1.91 -0.38 (-16.59%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.03 (+1.31%)

As of 07:44 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Aquestive Therapeutics NASDAQ:AQST

$3.78 -0.08 (-2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$3.90 +0.12 (+3.04%)

As of 07:36 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Arcturus Therapeutics NASDAQ:ARCT

$14.89 +3.50 (+30.73%)

Closing price 04:00 PM Eastern

Extended Trading

$14.87 -0.02 (-0.13%)

As of 07:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Solid Biosciences NASDAQ:SLDB

$6.04 -0.04 (-0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$6.20 +0.16 (+2.57%)

As of 07:31 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time